ABBV
AbbVie Inc. · Healthcare · Drug Manufacturers - General
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | +1 | 2.86M | $728.95M | +1 | n/a |
| Q2 2026 | 183 | +6 | 1.07B | $270.16B | +9 | −2 |
| Q1 2026 | 179 | -3 | 1.05B | $227.15B | +2 | −6 |
| Q4 2025 | 181 | -3 | 1.14B | $259.75B | +1 | −3 |
| Q3 2025 | 27 | 0 | 673.15M | $155.83B | n/a | −1 |
| Q2 2025 | 25 | +2 | 519.81M | $96.45B | +2 | n/a |
| Q1 2025 | 20 | 0 | 175.76M | $36.80B | n/a | n/a |
| Q4 2024 | 20 | 0 | 178.61M | $31.72B | n/a | n/a |
| Q3 2024 | 19 | 0 | 95.00M | $18.73B | +1 | −1 |
| Q2 2024 | 19 | n/a | 90.79M | $15.55B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 1.69M | -59.6% | $443.24M | 0.4% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 763.18K | +32.4% | $180.23M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 402.56K | +9.9% | $104.73M | 0.3% | ▲ Add | 4 | SEC ↗ |
| 4 | Ninety One UK Ltd | 2.85K | New | $745,532 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Ninety One UK Ltd | $745,532 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4,042 holders, 1.24B shares, $260.03B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 32.71K sh · $8.18M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology